Changes of heart function after different cell type stem cell transplantation in chronic heart failure.
- Author:
Zhongcai FAN
1
;
Mao CHEN
;
Juelin DENG
;
Xiaojing LIU
;
Li ZHANG
;
Li RAO
;
Qing YANG
;
Dejia HUANG
Author Information
1. Department of Cardiology, West China Hospital, Sichuan University, Chengdu 610041, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Bone Marrow Transplantation;
Chronic Disease;
Coronary Vessels;
Heart Failure;
physiopathology;
surgery;
Infusions, Intra-Arterial;
Mesenchymal Stem Cell Transplantation;
Myoblasts, Skeletal;
transplantation;
Rabbits;
Random Allocation;
Stem Cell Transplantation;
methods;
Troponin;
metabolism;
Ventricular Function, Left;
physiology
- From:
Journal of Biomedical Engineering
2006;23(6):1284-1288
- CountryChina
- Language:Chinese
-
Abstract:
To investigate the feasibility of introcoronary cell infusion into nonischemic heart failure (HF) heart and whether different types of stem cell transplantation would affect heart function to a similar degree. Japanese white ears rabbits were used as HF models by intravenous injection adriamycin. Autologous bone marrow mononuclear cells(BMCs), bone marrow stromal cells (MSCs), skeletal myoblasts (SMs) or culture medium were infused into coronary arteries respectively by occluding the root of ascending aorta. The mortality during and 4 weeks after the procedure the mortality was 7.1% and 16.7% respectively. After 4 weeks, the ejection fraction (EF) in BMCs group had significant improvement (P < 0.05, n=8). No significant difference was seen in MSCs (n =8), SMs (n=6) and sham groups (n=8) compared with pretransplantation (P > 0.05). In sham group,the left ventricular endostolic diameter (LVED) had significant enlargement (P < 0.05), No significant difference was seen in MBCs, MSCs and SMs groups compared with pretransplantation (P > 0.05). Immunofluorescence revealed de novo expression of cardiac troponin I in BMCs and MSCs groups, cardiac troponin I was not detected in SMs group. In conclusions, intracoronary cell transplantation could provide effective cell delivery into dilated cardiomyopathy hearts and could be a useful strategy for treating CHF, BMCs cell transplantation may be the first choice in all the above cell types.
